Delivering an immune therapy into tumours instead of intravenously reduces adverse effects

A study found that injecting low doses of anticancer immunotherapy directly into tumors in advanced skin cancer patients reduced severe immune toxicity compared to high-dose intravenous administration, while maintaining antitumor efficacy. Pre-existing antitumor immunity was the strongest predictor of clinical benefit, and fresh tissue profiling provided faster biomarker results than conventional diagnostics.